DBT-RGCB
@RGCB_Trivandrum
Followers
6K
Following
229
Media
1K
Statuses
2K
An R&D Institution of Biotechnology Research and Innovation Council (BRIC), Department of Biotechnology, Government of India
Thiruvananthapuram, India
Joined June 2015
4/4 The manuscript can be accessed from Dr Sara Jones from BRIC-RGCB shared equal first authorship.
jamanetwork.com
This cohort study of children and mothers from 2 provinces in India examines rates of measles-specific antibody seropositivity among vaccinated children.
0
0
0
3/4 and Dr. Joshy Jacob (Emory University School of Medicine, Atlanta, USA). The outcome of the study was published in JAMA Network Open, and the title of the manuscript is "Low Measles Seropositivity in Vaccinated Children.".
1
0
0
Blazing-fast image creation – using just your voice. Try Grok Imagine.
283
568
3K
2/4 Professor M. Radhakrishna Pillai, former director of BRIC-RGCB, was the principal investigator of the project. The study was done in collaboration with Dr Richard Kennedy (Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, USA).
1
0
0
1/4 #BRICRGCB received funding from the National Institute of Health (NIH), USA, to study measles-specific antibody seroprevalence among vaccinated children in southern India. @DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt
1
0
0
4/4 Prof. Valsamma Joseph, Director, National Centre for Aquatic Animal Health, CUSAT. The program was coordinated by Dr. Divya Purushothaman, Facility Manager, BioNest.
0
0
0
3/4 Dr. Nitesh Dave, Ex. Senior Director, Biocon/Freelance Consultant, Bangalore; Moderator, Dr. C.N. Ramchand, Founder & CEO, MagGenome Technologies; Dr. Radhakrishnan E.K., Assoc. Professor & Director of Business Innovation and Incubation Centre (BIIC), MG University;.
1
0
0
2/4 The panelists from right: Dr. C. Balagopal, Chairman, KSIDC; Dr. Gopala K. Dasika, Advisor, Life Sciences, Govt. of Tamil Nadu; Dr. Partha P. Hazra, R&D CoE Lead (Biotherapeutics), Biocon Biologics, Bangalore;.
1
0
0
1/4 To celebrate the BioE3 Pakhwada, #BRIC-RGCB organized a panel discussion and ideathon on "Foster high-performance biomanufacturing" on 29th August 2025 at KRIBS-BioNest, Kochi. @DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt
1
0
1
2/2 Various sports activities were organized. Dr Lightson N G, Scientist, BRIC-RGCB, administered the pledge. #NSD2025.#FitIndiaMovement.#KhelegaDeshKhilegeDesh.
0
0
0
1/2 #BRICRGCB celebrated National Sports Day on 29th August 2025 to honor the birth anniversary of Major Dhyan Chand. @DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt .@IndiaSports.@FitIndiaOff.@mygovindia
1
0
1
2/2 . of Dr. T R Santhosh Kumar at the Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala. Last Date: September 15, 2025 For more details please visit
rgcb.res.in
0
1
2
1/2 Applications are invited from Indians for 1 position of Project Associate II in the DBT-funded project titled Geometry Directed Functional Programming of Peptide-Based Drug Delivery. @DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt7510
1
2
4
2/2 A Nobel quest for knowledge at the interface of chemistry and biology.” Earlier Professor Chandrabhas Narayana, Director, #BRICRGCB, formally welcomed Dr. Meldal for the talk.
0
0
0
1/2 3rd RGCB Research Conference: Highlight Day 3. Prof. Morton Meldal, University of Copenhagen and Nobel Prize laureate in Chemistry (2022), delivered a special lecture on “Everything is chemistry:.@DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt
2
1
1
3/3 Dr. K. R. Mahendran, Scientist, #BRICRGCB, was the next speaker and delivered a talk on "Single-Peptide Assembly of Dual-Diameter α-Helical Nanopores for Pathological Protein Detection.".
0
0
0
2/3 The introductory talk was given by Dr. Raghu Kalluri, UT MD Anderson Cancer Center, Houston, USA, on the topic "Cancer without Disease: Exploring A Novel and Practical Strategy for Prevention and Control of Malignant Cancer.".
1
0
0
1/3 3rd RGCB Research Conference: Highlight Day 1: Professor Chandrabhas Narayana welcomed the gathering for the meeting. Dr. S. Asha Nair, convenor, provided an overview of the program. @DrJitendraSingh.@rajesh_gokhale.@DBTIndia.@IndiaDST.@BricDbt
1
1
3
4/4 BRIC-RGCB has received an upfront payment from Primordia, marking a significant milestone in the transfer agreement regarding recombinant cell lines. The payment was presented to Prof. Chandrabhas Narayana, Director of BRIC-RGCB, by Dr. Anu Yamuna Joseph, MD of Primordia.
0
0
0
3/4 Primordia will utilize this technology to develop affordable, real-time compatible apoptosis detection kits in various formats, enabling multiplexing for target-specific drug discovery.
1
0
0
2/4 BRIC-RGCBh has established a strategic partnership with Primordia Life Sciences Pvt. Ltd. through a Technology Transfer Agreement. This collaboration focuses on the commercialization of innovative apoptosis detection reagents for drug discovery.
1
0
0